Peripheral T cell lymphoma, not otherwise specified

The stuff of genes, dreams and therapies

C. Agostinelli, P. P. Piccaluga, P. Went, M. Rossi, A. Gazzola, S. Righi, T. Sista, C. Campidelli, P. L. Zinzani, B. Falini, Stefano A. Pileri

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Peripheral T cell lymphomas (PTCL) account for about 12% of lymphoid tumours worldwide. Almost half show such morphological and molecular variability as to hamper any further classification, and to justify their inclusion in a waste-basket category termed "not otherwise specified (NOS)". The latter term is used for neoplasms with aggressive presentation, poor response to therapy and dismal prognosis. In contrast to B cell lymphomas, PTCL have been the subject of only a limited number of studies to elucidate their pathobiology and identify novel pharmacological approaches. Herewith, the authors revise the most recent contributions on the subject based on the experience they have gained in the extensive application of microarray technologies. PTCL/NOS are characterised by erratic expression of T cell associated antigens, including CD4 and CD52, which have recently been proposed as targets for ad hoc immunotherapies. PTCL/NOS also show variable Ki-67 marking, with rates >80% heralding a worse prognosis. Gene expression profiling studies have revealed that PTCL/NOS derive from activated T lymphocytes, more often of the CD4+ type, and bear a signature composed of 155 genes and related products that play a pivotal role in cell signalling transduction, proliferation, apoptosis and matrix remodelling. This observation seems to pave the way for the use of innovative drugs such as tyrosine kinase and histone deacetylase inhibitors whose efficacy has been proven in PTCL primary cell cultures. Gene expression profiling also allows better distinction of PTCL/NOS from angioimmunoblastic T cell lymphoma, the latter being characterised by follicular T helper lymphocyte derivation and CXCL13, PD1 and vascular endothelial growth factor expression.

Original languageEnglish
Pages (from-to)1160-1167
Number of pages8
JournalJournal of Clinical Pathology
Volume61
Issue number11
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Peripheral T-Cell Lymphoma
Genetic Therapy
Gene Expression Profiling
T-Lymphocytes
CD4 Antigens
Histone Deacetylase Inhibitors
Primary Cell Culture
T-Cell Lymphoma
B-Cell Lymphoma
Helper-Inducer T-Lymphocytes
Protein-Tyrosine Kinases
Immunotherapy
Vascular Endothelial Growth Factor A
Neoplasms
Pharmacology
Apoptosis
Technology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Peripheral T cell lymphoma, not otherwise specified : The stuff of genes, dreams and therapies. / Agostinelli, C.; Piccaluga, P. P.; Went, P.; Rossi, M.; Gazzola, A.; Righi, S.; Sista, T.; Campidelli, C.; Zinzani, P. L.; Falini, B.; Pileri, Stefano A.

In: Journal of Clinical Pathology, Vol. 61, No. 11, 11.2008, p. 1160-1167.

Research output: Contribution to journalArticle

Agostinelli, C, Piccaluga, PP, Went, P, Rossi, M, Gazzola, A, Righi, S, Sista, T, Campidelli, C, Zinzani, PL, Falini, B & Pileri, SA 2008, 'Peripheral T cell lymphoma, not otherwise specified: The stuff of genes, dreams and therapies', Journal of Clinical Pathology, vol. 61, no. 11, pp. 1160-1167. https://doi.org/10.1136/jcp.2008.055335
Agostinelli, C. ; Piccaluga, P. P. ; Went, P. ; Rossi, M. ; Gazzola, A. ; Righi, S. ; Sista, T. ; Campidelli, C. ; Zinzani, P. L. ; Falini, B. ; Pileri, Stefano A. / Peripheral T cell lymphoma, not otherwise specified : The stuff of genes, dreams and therapies. In: Journal of Clinical Pathology. 2008 ; Vol. 61, No. 11. pp. 1160-1167.
@article{76f871c19b844be0896e508dc511d9e6,
title = "Peripheral T cell lymphoma, not otherwise specified: The stuff of genes, dreams and therapies",
abstract = "Peripheral T cell lymphomas (PTCL) account for about 12{\%} of lymphoid tumours worldwide. Almost half show such morphological and molecular variability as to hamper any further classification, and to justify their inclusion in a waste-basket category termed {"}not otherwise specified (NOS){"}. The latter term is used for neoplasms with aggressive presentation, poor response to therapy and dismal prognosis. In contrast to B cell lymphomas, PTCL have been the subject of only a limited number of studies to elucidate their pathobiology and identify novel pharmacological approaches. Herewith, the authors revise the most recent contributions on the subject based on the experience they have gained in the extensive application of microarray technologies. PTCL/NOS are characterised by erratic expression of T cell associated antigens, including CD4 and CD52, which have recently been proposed as targets for ad hoc immunotherapies. PTCL/NOS also show variable Ki-67 marking, with rates >80{\%} heralding a worse prognosis. Gene expression profiling studies have revealed that PTCL/NOS derive from activated T lymphocytes, more often of the CD4+ type, and bear a signature composed of 155 genes and related products that play a pivotal role in cell signalling transduction, proliferation, apoptosis and matrix remodelling. This observation seems to pave the way for the use of innovative drugs such as tyrosine kinase and histone deacetylase inhibitors whose efficacy has been proven in PTCL primary cell cultures. Gene expression profiling also allows better distinction of PTCL/NOS from angioimmunoblastic T cell lymphoma, the latter being characterised by follicular T helper lymphocyte derivation and CXCL13, PD1 and vascular endothelial growth factor expression.",
author = "C. Agostinelli and Piccaluga, {P. P.} and P. Went and M. Rossi and A. Gazzola and S. Righi and T. Sista and C. Campidelli and Zinzani, {P. L.} and B. Falini and Pileri, {Stefano A.}",
year = "2008",
month = "11",
doi = "10.1136/jcp.2008.055335",
language = "English",
volume = "61",
pages = "1160--1167",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Peripheral T cell lymphoma, not otherwise specified

T2 - The stuff of genes, dreams and therapies

AU - Agostinelli, C.

AU - Piccaluga, P. P.

AU - Went, P.

AU - Rossi, M.

AU - Gazzola, A.

AU - Righi, S.

AU - Sista, T.

AU - Campidelli, C.

AU - Zinzani, P. L.

AU - Falini, B.

AU - Pileri, Stefano A.

PY - 2008/11

Y1 - 2008/11

N2 - Peripheral T cell lymphomas (PTCL) account for about 12% of lymphoid tumours worldwide. Almost half show such morphological and molecular variability as to hamper any further classification, and to justify their inclusion in a waste-basket category termed "not otherwise specified (NOS)". The latter term is used for neoplasms with aggressive presentation, poor response to therapy and dismal prognosis. In contrast to B cell lymphomas, PTCL have been the subject of only a limited number of studies to elucidate their pathobiology and identify novel pharmacological approaches. Herewith, the authors revise the most recent contributions on the subject based on the experience they have gained in the extensive application of microarray technologies. PTCL/NOS are characterised by erratic expression of T cell associated antigens, including CD4 and CD52, which have recently been proposed as targets for ad hoc immunotherapies. PTCL/NOS also show variable Ki-67 marking, with rates >80% heralding a worse prognosis. Gene expression profiling studies have revealed that PTCL/NOS derive from activated T lymphocytes, more often of the CD4+ type, and bear a signature composed of 155 genes and related products that play a pivotal role in cell signalling transduction, proliferation, apoptosis and matrix remodelling. This observation seems to pave the way for the use of innovative drugs such as tyrosine kinase and histone deacetylase inhibitors whose efficacy has been proven in PTCL primary cell cultures. Gene expression profiling also allows better distinction of PTCL/NOS from angioimmunoblastic T cell lymphoma, the latter being characterised by follicular T helper lymphocyte derivation and CXCL13, PD1 and vascular endothelial growth factor expression.

AB - Peripheral T cell lymphomas (PTCL) account for about 12% of lymphoid tumours worldwide. Almost half show such morphological and molecular variability as to hamper any further classification, and to justify their inclusion in a waste-basket category termed "not otherwise specified (NOS)". The latter term is used for neoplasms with aggressive presentation, poor response to therapy and dismal prognosis. In contrast to B cell lymphomas, PTCL have been the subject of only a limited number of studies to elucidate their pathobiology and identify novel pharmacological approaches. Herewith, the authors revise the most recent contributions on the subject based on the experience they have gained in the extensive application of microarray technologies. PTCL/NOS are characterised by erratic expression of T cell associated antigens, including CD4 and CD52, which have recently been proposed as targets for ad hoc immunotherapies. PTCL/NOS also show variable Ki-67 marking, with rates >80% heralding a worse prognosis. Gene expression profiling studies have revealed that PTCL/NOS derive from activated T lymphocytes, more often of the CD4+ type, and bear a signature composed of 155 genes and related products that play a pivotal role in cell signalling transduction, proliferation, apoptosis and matrix remodelling. This observation seems to pave the way for the use of innovative drugs such as tyrosine kinase and histone deacetylase inhibitors whose efficacy has been proven in PTCL primary cell cultures. Gene expression profiling also allows better distinction of PTCL/NOS from angioimmunoblastic T cell lymphoma, the latter being characterised by follicular T helper lymphocyte derivation and CXCL13, PD1 and vascular endothelial growth factor expression.

UR - http://www.scopus.com/inward/record.url?scp=56049100260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049100260&partnerID=8YFLogxK

U2 - 10.1136/jcp.2008.055335

DO - 10.1136/jcp.2008.055335

M3 - Article

VL - 61

SP - 1160

EP - 1167

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 11

ER -